Portal de Periódicos da CAPES

Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS

2017; Elsevier BV; Volume: 18; Issue: 11 Linguagem: Inglês

10.1016/s1470-2045(17)30785-4

1474-5488

Sung‐Bae Kim, Rebecca Dent, Matthew Wongchenko, Stina Mui Singel, José Baselga,

Genetic factors in colorectal cancer

We thank Delaloge and DeForceville 1 Delaloge S DeForceville L Targeting PI3K/AKT pathway in triple-negative breast cancer. Lancet Oncol. 2017; 18: 1293-1294 Summary Full Text Full Text PDF PubMed Scopus (37) Google Scholar for raising several important points in their Comment on results from LOTUS, 2 Kim S-B Dent R Im S-A et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017; 18: 1360-1372 Summary Full Text Full Text PDF PubMed Scopus (306) Google Scholar a randomised, phase 2 trial investigating the addition of ipatasertib to paclitaxel as first-line therapy for metastatic triple-negative breast cancer. Specifically, they expressed concern over tissue-based diagnostics, given the spatial and temporal heterogeneity observed in triple-negative breast cancer. They remarked that if, as suggested in LOTUS, genomic alterations are the preferred biomarker, circulating tumour (ct) DNA methods might be useful in improving therapeutic targeting. Compared with tissue sequencing, ctDNA sequencing could offer improved time efficiency (avoiding the need to retrieve tissue blocks or perform biopsy), reduced invasiveness, and the possibility of sampling multiple DNA-shedding lesions rather than a single tumour by biopsy. 3 Sellami D Dharan B Wilke C Scherer SJ Hirawat S Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors. Ann Oncol. 2017; (published online Sept 5.)DOI:10.1093/annonc/mdx480 Summary Full Text Full Text PDF PubMed Scopus (4) Google Scholar , 4 Canzoniero JV Park BH Use of cell free DNA in breast oncology. Biochim Biophys Acta. 2016; 1865: 266-274 PubMed Google Scholar However, concordance between tissue-based and ctDNA-based next-generation sequencing (NGS) data has been variable. 3 Sellami D Dharan B Wilke C Scherer SJ Hirawat S Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors. Ann Oncol. 2017; (published online Sept 5.)DOI:10.1093/annonc/mdx480 Summary Full Text Full Text PDF PubMed Scopus (4) Google Scholar The poor concordance described in some tumour types 5 Barata PC Koshkin VS Funchain P et al. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Ann Oncol. 2017; 28: 2458-2463 Summary Full Text Full Text PDF PubMed Scopus (55) Google Scholar , 6 Kuderer NM Burton KA Blau S et al. Comparison of 2 commercially available next-generation sequencing platforms in oncology. JAMA Oncol. 2017; 3: 996-998 Crossref PubMed Scopus (116) Google Scholar is potentially attributable to tumour evolution. Targeting PI3K/AKT pathway in triple-negative breast cancerMetastatic triple-negative breast cancer has one of the worst prognoses of all cancers. Its associated median overall survival of only 13 months has not changed for almost two decades despite many efforts to develop alternative approaches to chemotherapy, including targeting angiogenesis, DNA repair, and EGFR.1 Potential explanations are the very heterogeneous and unstable nature of this disease, together with the absence of known leading oncogenic drivers.1,2 Full-Text PDF Correction to Lancet Oncol 2017; 18: e638Kim SB, Dent R, Wongchenko MJ, Singel SM, Baselga J; LOTUS investigators. Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS. Lancet Oncol 2017; 18: e638—In the Declaration of interests section of this Correspondence, Jose Baselga's declarations should read “JB reports non-financial support from Roche/Genentech during the conduct of the study; personal fees and stock from Aura Biosciences, Northern Biologics (f/k/a Mosaic Biomedicals), Infinity Pharmaceuticals, PMV Pharma, Juno Therapeutics, TANGO (f/k/a Synthetic Lethal), GRAIL, Varian Medical Systems and Seragon; stock from ApoGen Biotechnologies and Foghorn Therapeutics; personal fees and non-financial support from Novartis and Eli Lilly; and non-financial support from Daiichi Sankyo and Bristol Myers Squibb, outside the submitted work”. Full-Text PDF